HRP20200351T1 - Cikloalkinski derivati saharida - Google Patents

Cikloalkinski derivati saharida Download PDF

Info

Publication number
HRP20200351T1
HRP20200351T1 HRP20200351TT HRP20200351T HRP20200351T1 HR P20200351 T1 HRP20200351 T1 HR P20200351T1 HR P20200351T T HRP20200351T T HR P20200351TT HR P20200351 T HRP20200351 T HR P20200351T HR P20200351 T1 HRP20200351 T1 HR P20200351T1
Authority
HR
Croatia
Prior art keywords
saccharide
conjugate
group
azide
spacer
Prior art date
Application number
HRP20200351TT
Other languages
English (en)
Croatian (hr)
Inventor
Roberto ADAMO
Francesco Berti
Qi-Ying Hu
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20200351T1 publication Critical patent/HRP20200351T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20200351TT 2013-01-15 2014-01-13 Cikloalkinski derivati saharida HRP20200351T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
EP14700602.7A EP2945641B1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (1)

Publication Number Publication Date
HRP20200351T1 true HRP20200351T1 (hr) 2020-06-12

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200351TT HRP20200351T1 (hr) 2013-01-15 2014-01-13 Cikloalkinski derivati saharida

Country Status (16)

Country Link
US (2) US11135300B2 (cg-RX-API-DMAC7.html)
EP (1) EP2945641B1 (cg-RX-API-DMAC7.html)
JP (3) JP6719209B2 (cg-RX-API-DMAC7.html)
CN (1) CN105377282B (cg-RX-API-DMAC7.html)
BR (1) BR112015016817B1 (cg-RX-API-DMAC7.html)
CA (1) CA2897348C (cg-RX-API-DMAC7.html)
CY (1) CY1122822T1 (cg-RX-API-DMAC7.html)
DK (1) DK2945641T3 (cg-RX-API-DMAC7.html)
ES (1) ES2774729T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300707D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20200351T1 (cg-RX-API-DMAC7.html)
LT (1) LT2945641T (cg-RX-API-DMAC7.html)
PL (1) PL2945641T3 (cg-RX-API-DMAC7.html)
PT (1) PT2945641T (cg-RX-API-DMAC7.html)
SI (1) SI2945641T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014111344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
SG11201807430WA (en) * 2016-03-04 2018-09-27 Euglena Co Ltd Antiviral agent and antiviral food
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US12050220B2 (en) 2018-02-05 2024-07-30 University Of Miyazaki Cell labeling agent and cell labeling kit
EP3808783A4 (en) 2018-06-14 2022-03-16 Mochida Pharmaceutical Co., Ltd. Novel crosslinked alginic acid
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2022040266A1 (en) 2020-08-19 2022-02-24 Vaxcyte, Inc. Carrier-protein polysaccharide conjugation methods
BR112023023671A2 (pt) * 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
AU2005302269B2 (en) 2004-11-01 2011-05-19 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CN104529711B (zh) * 2007-11-21 2020-02-07 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
ES2527536T7 (es) 2010-04-27 2016-03-08 Synaffix B.V. Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9315468B2 (en) 2010-09-27 2016-04-19 University Of Georgia Research Foundation, Inc. Methods including latent 1,3-dipole-functional compounds and materials prepared thereby
US20120208722A1 (en) * 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
AU2012344700A1 (en) * 2011-12-01 2014-06-19 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Also Published As

Publication number Publication date
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15
CY1122822T1 (el) 2021-05-05
PT2945641T (pt) 2020-03-26
US11135300B2 (en) 2021-10-05
US12409231B2 (en) 2025-09-09
CN105377282B (zh) 2020-07-17
SI2945641T1 (sl) 2020-03-31
US20160166704A1 (en) 2016-06-16
WO2014111344A1 (en) 2014-07-24
CN105377282A (zh) 2016-03-02
CA2897348C (en) 2022-09-27
JP2016506905A (ja) 2016-03-07
BR112015016817B1 (pt) 2020-11-10
EP2945641A1 (en) 2015-11-25
ES2774729T3 (es) 2020-07-22
BR112015016817A2 (pt) 2017-07-11
BR112015016817A8 (pt) 2019-10-29
DK2945641T3 (da) 2020-03-09
LT2945641T (lt) 2020-02-25
JP2019073528A (ja) 2019-05-16
CA2897348A1 (en) 2014-07-24
JP2020114839A (ja) 2020-07-30
GB201300707D0 (en) 2013-02-27
EP2945641B1 (en) 2020-01-01
US20210268116A1 (en) 2021-09-02
JP7036854B2 (ja) 2022-03-15

Similar Documents

Publication Publication Date Title
HRP20200351T1 (hr) Cikloalkinski derivati saharida
JP2016506905A5 (cg-RX-API-DMAC7.html)
Still et al. Alkaloids from Microcos paniculata with cytotoxic and nicotinic receptor antagonistic activities
WO2018098269A3 (en) Peptide-containing linkers for antibody-drug conjugates
Shoaib et al. Scientific investigation of crude alkaloids from medicinal plants for the management of pain
MX2009013508A (es) Composicion plaguicida que comprende un derivado de estrigolactona y un compuesto insecticida.
UY31867A (es) Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
GT200400174A (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4
CO6450634A2 (es) Composiciones plaguicidas
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2015134464A3 (en) Targeted therapeutics
WO2015066053A8 (en) Targeted therapeutics
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
NO20080302L (no) Humane anti-B7RP1 noytraliserende antistoffer
EA201591425A1 (ru) Мультивалентные гликоконъюгатные вакцины
Fonseca-Berzal et al. Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles
JP2017505777A5 (cg-RX-API-DMAC7.html)
NZ715646A (en) Antibody drug conjugates
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
FI2766364T3 (fi) Albumiinia sitovien entiteettien folaattikonjugaatit
EP2548552A3 (en) Titration package for 1-amino-alkylcylohexanes
CY1115926T1 (el) Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης
Leewanich et al. Behavioral studies on alkaloids extracted from the leaves of Hunteria zeylanica
RU2021101009A (ru) Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство
BR112018000909A2 (pt) imunoconjugados de il22